Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

David PlanchardMichael J BoyerJong-Seok LeeArunee DechaphunkulParneet K CheemaToshiaki TakahashiJhanelle E GrayMarcello TiseoSuresh S RamalingamAlexander ToddAstrid McKeownYuri RukazenkovYuichiro Ohe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

All postprogression endpoints showed consistent improvement with osimertinib versus SoC EGFR-TKI, providing further confidence in the interim OS data.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
small cell lung cancer
healthcare
palliative care
electronic health record
big data
adipose tissue
glycemic control